30 completed. 30 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 30 | Completed 30 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 3 | Completed 3 |
Follow Disease Progression: new trials by email Literature Review of Disease Progression trials Research Report on Disease Progression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact Of Metformin In Rectal Cancer Patients Metformin - Rectal Cancer Patients | Phase 2 / Phase 3 | Completed | Minia University | 85 | 2024-05-01 | 2025-08-01 |
| Propionic Acid in Multiple Sclerosis Propionic acid 1000 mg capsule, Placebo - Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Salzburger Landeskliniken | 101 | 2024-05-01 | 2026-09-15 |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors certepetide, Durvalumab, Cisplatin - Cholangiocarcinoma, Gallbladder Cancer | Phase 2 | Completed | Lisata Therapeutics, Inc. | 66 | 2023-05-13 | 2026-09-28 |
| PTC Guiding Neoadjuvant Treatment in Breast Cancer patient-derived tumor-like cell clusters drug sensitivity test - Pathological Conditions, Signs and Symptoms | Phase 2 | Completed | Zhejiang Cancer Hospital | 86 | 2021-11-01 | 2023-12-27 |
| Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, ARVI Rutan 25 mg, Control group - COVID-19 Respiratory Infection | Phase 2 | Completed | Research Institute of Virology, Ministry of Health of the Republic of Uzbekistan | 301 | 2021-06-01 | 2023-05-17 |
| Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma Pembrolizumab Injection - Esophageal Squamous Cell Carcinoma | Phase 2 | Completed | Ruijin Hospital | 143 | 2020-08-11 | 2024-07-03 |
| Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia Gemtuzumab Ozogamicin (GO), Donor Leukocytes - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Brown University | 11 | 2019-12-31 | 2026-07-23 |
| Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Avelumab, Axitinib - Metastatic Adenoid Cystic Carcinoma, Progressive Disease | Phase 2 | Completed | M.D. Anderson Cancer Center | 40 | 2019-07-22 | 2024-10-18 |
| FLYSYN in MRD Positive AML FLYSYN - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Synimmune GmbH | 31 | 2017-02-07 | 2023-12-28 |
| NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018) NGR-hTNF, Pegylated liposomal doxorubicin, Doxorubicin - Ovarian Cancer | Phase 2 | Completed | AGC Biologics S.p.A. | 14 | 2013-03-01 | 2019-01-15 |
| Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive BKM120 - Head and Neck Neoplasms, Neoplasm Metastasis | Phase 2 | Completed | Centre Leon Berard | 58 | 2013-01-01 | 2019-06-24 |
| Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) Pazopanib, Temsirolimus, Quality of Life Assessment - Kidney Cancer | Phase 2 | Completed | M.D. Anderson Cancer Center | 69 | 2012-10-24 | 2021-09-20 |
| Preoperative Radiochemotherapy With Hyperthermia for Locally Advanced Rectal Cancer Deep regional hyperthermia, Radiotherapy, Chemotherapy (5-Fluorouracil) - Rectal Cancer, Locally Advanced Rectal Cancer | Phase 2 | Completed | University Hospital Tuebingen | 78 | 2012-08-01 | 2018-02-13 |
| Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis Tcelna, Placebo - Autoimmune Diseases of the Nervous System, Multiple Sclerosis | Phase 2 | Completed | Opexa Therapeutics, Inc. | 183 | 2012-08-01 | 2017-01-10 |
| Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer NGR-hTNF, Pegylated liposomal doxorubicin, Doxorubicin - Ovarian Cancer | Phase 2 | Completed | AGC Biologics S.p.A. | 119 | 2011-06-01 | 2018-09-27 |
| Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer Trastuzumab - HER-2 Positive Breast Cancer | Phase 2 | Completed | Lucia Del Mastro,MD | 43 | 2011-03-01 | 2024-05-09 |
| Bee Venom for the Treatment of Parkinson Disease bee venom - Parkinson Disease | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 50 | 2011-03-01 | 2014-06-16 |
| WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Galinpepimut-S, GM-CSF, Montanide - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Completed | Sellas Life Sciences Group | 22 | 2011-01-14 | 2024-11-19 |
| 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer 5-Fluorouracil, Leucovorin, Oxaliplatin - Gastric Cancer | Phase 2 / Phase 3 | Completed | Krankenhaus Nordwest | 716 | 2010-08-01 | 2019-06-19 |
| A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas ZD6474 (Vandetanib), Carboplatin - Glioblastoma Multiforme, Gliosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 112 | 2009-09-01 | 2016-03-29 |
Showing 20 of 30. Sign in to see all of them.
Pathologic Complete Response (11) · Neoplasm Metastasis (5) · Leukemia, Myeloid, Acute (3) · Ovarian Neoplasms (3) · Recurrence (3) · Brain Neoplasms (2) · Breast Neoplasms (2) · Glioma (2) · Multiple Sclerosis (2) · Parkinson Disease (2) · Acquired Immunodeficiency Syndrome (1) · Astrocytoma (1) · Autoimmune Diseases of the Nervous System (1) · Bile Duct Neoplasms (1)
Disease Attributes (30) · Pathologic Processes (30) · Pathological Conditions, Signs and Symptoms (29) · Neoplasms (19) · Neoplasms by Site (15) · Neoplasms by Histologic Type (11) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Immune System Diseases (6) · Neoplasms, Glandular and Epithelial (6) · Nervous System Diseases (6) · Urogenital Diseases (6) · Genital Diseases (5) · Neoplastic Processes (5)
Bortezomib (3) · Fluorouracil (3) · Cisplatin (2) · Doxorubicin (2) · Leucovorin (2) · Oxaliplatin (2) · liposomal doxorubicin (2) · tumor necrosis factor-alpha, CNGRC fusion protein, human (2) · Axitinib (1) · Bee Venoms (1) · CP protocol (1) · Carboplatin (1) · Control Groups (1) · Cyclophosphamide (1) · Dexamethasone (1)
AGC Biologics S.p.A. (2) · M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (2) · ARCAGY/ GINECO GROUP (1) · Assistance Publique - Hôpitaux de Paris (1) · Brown University (1) · Centre Leon Berard (1) · Institute for Neurodegenerative Disorders (1) · Janssen-Cilag International NV (1) · Krankenhaus Nordwest (1) · Lisata Therapeutics, Inc. (1) · Lucia Del Mastro,MD (1) · Medical Mission Institute, Germany (1) · Millennium Pharmaceuticals, Inc. (1) · Minia University (1)
United States (10) · France (4) · Germany (4) · China (3) · Italy (3) · Turkey (Türkiye) (2) · United Kingdom (2) · Austria (1) · Belgium (1) · Canada (1) · Egypt (1) · Greece (1) · Hungary (1) · Lithuania (1) · Poland (1)
Antonio Lambiase, MD (2) · Amado Zurita, MD (1) · Andreas Hartmann, MD (1) · August HR Stich, MD MSc (1) · Danna Jennings, MD (1) · Erkin Musabaev, professor (1) · Fatma M Mady, professor (1) · Hecheng Li, MD&PHD (1) · Helmut Salih, Prof. Dr. (1) · Jessica Jackson (1) · John Reagan, MD (1) · Katherine E Warren, M.D. (1) · Katherine Warren, M.D. (1)
PMID 19008157, PMID 19692142, PMID 20211870, PMID 23592699, PMID 25261096, PMID 26285768, PMID 26571268, PMID 26812052, PMID 27403743, PMID 27776843, PMID 29386195, PMID 30982686, PMID 31639132, PMID 33373868, PMID 33741467, PMID 36003437, PMID 36375981, PMID 36898078, PMID 37146227, PMID 37587502, PMID 38093975, PMID 41309527, PMID 41780143, PMID 42456199
2023 (1)